Shiv Kumar Viswanathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shiv Kumar Viswanathan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Sakthivel Sadayappan
Heart, Lung and Vascular Institute, Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH 45267, USA
3 shared publications Aravindakshan Jagadeesan
Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, Illinois
2 shared publications- Ralph Knöll
National Heart and Lung Institute, Imperial College London, London, W12 0NN, United Kingdom
2 shared publications A Jamil Tajik
Aurora Cardiovascular Services, St. Luke's Medical Center, Milwaukee, Wisconsin, United States of America
1 shared publicationAaron Cooper
Department of Microbiology, Immunology and Molecular Genetics and the Eli & Edythe Broad Stem Cell Research Center, University of California, Los Angeles, California, USA
1 shared publication- Anantha Vijay R. Santhanam
Departments of Anesthesiology and Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA
1 shared publication
Latest Publications
- 1 June 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (6) , 481-488
Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants
Importance The genetic variantMYBPC3Δ25bpoccurs in 4% of South Asian descendants, with an estimated 100 million carriers worldwide.MYBPC3 Δ25bphas been linked to cardiomyopathy and heart failure. However, the high prevalence ofMYBPC3Δ25bpsuggests that other stressors act in concert withMYBPC3Δ25bp. Objective To determine whether there are additional genetic factors that contribute to the cardiomyopathic expression ofMYBPC3Δ25bp. Design, Setting, andParticipants South Asian individuals living in the United States were screened forMYBPC3Δ25bp, and a subgroup was clinically evaluated using electrocardiograms and echocardiograms at Loyola University, Chicago, Illinois, between January 2015 and July 2016. Main Outcomes and Measures Next-generation sequencing of 174 cardiovascular disease genes was applied to identify additional modifying gene mutations and correlate genotype-phenotype parameters. Cardiomyocytes derived from human-induced pluripotent stem cells were established and examined to assess the role ofMYBPC3Δ25bp. Results In this genotype-phenotype study, individuals of South Asian descent living in the United States from both sexes (36.23% female) with a mean population age of 48.92 years (range, 18-84 years) were recruited. Genetic screening of 2401 US South Asian individuals found anMYBPC3Δ25bpcarrier frequency of 6%. A higher frequency of missenseTTNvariation was found inMYBPC3Δ25bpcarriers compared with noncarriers, identifying distinct genetic backgrounds within theMYBPC3Δ25bpcarrier group. Strikingly, 9.6% ofMYBPC3Δ25bpcarriers also had a novelMYBPC3variant, D389V. Family studies documented D389V was in tandem on the same allele asMYBPC3Δ25bp, and D389V was only seen in the presence ofMYBPC3Δ25bp. In contrast toMYBPC3Δ25bp,MYBPC3Δ25bp/D389Vwas associated with hyperdynamic left ventricular performance (mean [SEM] left ventricular ejection fraction, 66.7 [0.7%]; left ventricular fractional shortening, 36.6 [0.6%];P < .03) and stem cell–derived cardiomyocytes exhibited cellular hypertrophy with abnormal Ca2+transients. Conclusions and Relevance MYBPC3Δ25bp/D389Vis associated with hyperdynamic features, which are an early finding in hypertrophic cardiomyopathy and thought to reflect an unfavorable energetic state. These findings support that a subset ofMYBPC3Δ25bpcarriers, those with D389V, account for the increased risk attributed toMYBPC3Δ25bp.
- 1 June 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (6) , 481-488
Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants
Importance The genetic variantMYBPC3Δ25bpoccurs in 4% of South Asian descendants, with an estimated 100 million carriers worldwide.MYBPC3 Δ25bphas been linked to cardiomyopathy and heart failure. However, the high prevalence ofMYBPC3Δ25bpsuggests that other stressors act in concert withMYBPC3Δ25bp. Objective To determine whether there are additional genetic factors that contribute to the cardiomyopathic expression ofMYBPC3Δ25bp. Design, Setting, andParticipants South Asian individuals living in the United States were screened forMYBPC3Δ25bp, and a subgroup was clinically evaluated using electrocardiograms and echocardiograms at Loyola University, Chicago, Illinois, between January 2015 and July 2016. Main Outcomes and Measures Next-generation sequencing of 174 cardiovascular disease genes was applied to identify additional modifying gene mutations and correlate genotype-phenotype parameters. Cardiomyocytes derived from human-induced pluripotent stem cells were established and examined to assess the role ofMYBPC3Δ25bp. Results In this genotype-phenotype study, individuals of South Asian descent living in the United States from both sexes (36.23% female) with a mean population age of 48.92 years (range, 18-84 years) were recruited. Genetic screening of 2401 US South Asian individuals found anMYBPC3Δ25bpcarrier frequency of 6%. A higher frequency of missenseTTNvariation was found inMYBPC3Δ25bpcarriers compared with noncarriers, identifying distinct genetic backgrounds within theMYBPC3Δ25bpcarrier group. Strikingly, 9.6% ofMYBPC3Δ25bpcarriers also had a novelMYBPC3variant, D389V. Family studies documented D389V was in tandem on the same allele asMYBPC3Δ25bp, and D389V was only seen in the presence ofMYBPC3Δ25bp. In contrast toMYBPC3Δ25bp,MYBPC3Δ25bp/D389Vwas associated with hyperdynamic left ventricular performance (mean [SEM] left ventricular ejection fraction, 66.7 [0.7%]; left ventricular fractional shortening, 36.6 [0.6%];P < .03) and stem cell–derived cardiomyocytes exhibited cellular hypertrophy with abnormal Ca2+transients. Conclusions and Relevance MYBPC3Δ25bp/D389Vis associated with hyperdynamic features, which are an early finding in hypertrophic cardiomyopathy and thought to reflect an unfavorable energetic state. These findings support that a subset ofMYBPC3Δ25bpcarriers, those with D389V, account for the increased risk attributed toMYBPC3Δ25bp.
- Open Access
- 9 November 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (11) , e0187948
Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage
Over 1,500 gene mutations are known to cause hypertrophic cardiomyopathy (HCM). Previous studies suggest that cardiac β-myosin heavy chain (MYH7) gene mutations are commonly associated with a more severe phenotype, compared to cardiac myosin binding protein-C (MYBPC3) gene mutations with milder phenotype, incomplete penetrance and later age of onset. Compound mutations can worsen the phenotype. This study aimed to validate these comparative differences in a large cohort of individuals and families with HCM. We performed genome-phenome correlation among 80 symptomatic HCM patients, 35 asymptomatic carriers and 35 non-carriers, using an 18-gene clinical diagnostic HCM panel. A total of 125 mutations were identified in 14 genes. MYBPC3 and MYH7 mutations contributed to 50.0% and 24.4% of the HCM patients, respectively, suggesting that MYBPC3 mutations were the most frequent cause of HCM in our cohort. Double mutations were found in only nine HCM patients (7.8%) who were phenotypically indistinguishable from single-mutation carriers. Comparisons of clinical parameters of MYBPC3 and MYH7 mutants were not statistically significant, but asymptomatic carriers had high left ventricular ejection fraction and diastolic dysfunction when compared to non-carriers. The presence of double mutations increases the risk for symptomatic HCM with no change in severity, as determined in this study subset. The pathologic effects of MYBPC3 and MYH7 were found to be independent of gene mutation location. Furthermore, HCM pathology is independent of protein domain disruption in both MYBPC3 and MYH7. These data provide evidence that MYBPC3 mutations constitute the preeminent cause of HCM and that they are phenotypically indistinguishable from HCM caused by MYH7 mutations.
- 9 November 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (11) , e0187948
Open AccessHypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage
Over 1,500 gene mutations are known to cause hypertrophic cardiomyopathy (HCM). Previous studies suggest that cardiac β-myosin heavy chain (MYH7) gene mutations are commonly associated with a more severe phenotype, compared to cardiac myosin binding protein-C (MYBPC3) gene mutations with milder phenotype, incomplete penetrance and later age of onset. Compound mutations can worsen the phenotype. This study aimed to validate these comparative differences in a large cohort of individuals and families with HCM. We performed genome-phenome correlation among 80 symptomatic HCM patients, 35 asymptomatic carriers and 35 non-carriers, using an 18-gene clinical diagnostic HCM panel. A total of 125 mutations were identified in 14 genes. MYBPC3 and MYH7 mutations contributed to 50.0% and 24.4% of the HCM patients, respectively, suggesting that MYBPC3 mutations were the most frequent cause of HCM in our cohort. Double mutations were found in only nine HCM patients (7.8%) who were phenotypically indistinguishable from single-mutation carriers. Comparisons of clinical parameters of MYBPC3 and MYH7 mutants were not statistically significant, but asymptomatic carriers had high left ventricular ejection fraction and diastolic dysfunction when compared to non-carriers. The presence of double mutations increases the risk for symptomatic HCM with no change in severity, as determined in this study subset. The pathologic effects of MYBPC3 and MYH7 were found to be independent of gene mutation location. Furthermore, HCM pathology is independent of protein domain disruption in both MYBPC3 and MYH7. These data provide evidence that MYBPC3 mutations constitute the preeminent cause of HCM and that they are phenotypically indistinguishable from HCM caused by MYH7 mutations.
- 1 September 2017
- Published by Elsevier in Cytotherapy
- Vol. 19 (9) , 1096-1112
Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease
- 1 September 2017
- Published by Elsevier in Cytotherapy
- Vol. 19 (9) , 1096-1112
Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease
- Open Access
- 28 October 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 499
Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants
The South Asian population, numbered at 1.8 billion, is estimated to comprise around 20% of the global population and 1% of the American population, and has one of the highest rates of cardiovascular disease. While South Asians show increased classical risk factors for developing heart failure, the role of population-specific genetic risk factors has not yet been examined for this group. Hypertrophic cardiomyopathy (HCM) is one of the major cardiac genetic disorders among South Asians, leading to contractile dysfunction, heart failure, and sudden cardiac death. This disease displays autosomal dominant inheritance, and it is associated with a large number of variants in both sarcomeric and non-sarcomeric proteins. South Asians, a population with large ethnic diversity, potentially carries region-specific polymorphisms. There is high variability in disease penetrance and phenotypic expression of variants associated with HCM. Thus, extensive studies are required to decipher pathogenicity and the physiological mechanisms of these variants, as well as the contribution of modifier genes and environmental factors to disease phenotypes. Conducting genotype-phenotype correlation studies will lead to improved understanding of HCM and, consequently, improved treatment options for this high-risk population. The objective of this review is to report the history of cardiovascular disease and HCM in South Asians, present previously published pathogenic variants, and introduce current efforts to study HCM using induced pluripotent stem cell-derived cardiomyocytes, next-generation sequencing, and gene editing technologies. The authors ultimately hope that this review will stimulate further research, drive novel discoveries, and contribute to the development of personalized medicine with the aim of expanding therapeutic strategies for HCM.
- 28 October 2016
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 499
Open AccessRecent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants
The South Asian population, numbered at 1.8 billion, is estimated to comprise around 20% of the global population and 1% of the American population, and has one of the highest rates of cardiovascular disease. While South Asians show increased classical risk factors for developing heart failure, the role of population-specific genetic risk factors has not yet been examined for this group. Hypertrophic cardiomyopathy (HCM) is one of the major cardiac genetic disorders among South Asians, leading to contractile dysfunction, heart failure, and sudden cardiac death. This disease displays autosomal dominant inheritance, and it is associated with a large number of variants in both sarcomeric and non-sarcomeric proteins. South Asians, a population with large ethnic diversity, potentially carries region-specific polymorphisms. There is high variability in disease penetrance and phenotypic expression of variants associated with HCM. Thus, extensive studies are required to decipher pathogenicity and the physiological mechanisms of these variants, as well as the contribution of modifier genes and environmental factors to disease phenotypes. Conducting genotype-phenotype correlation studies will lead to improved understanding of HCM and, consequently, improved treatment options for this high-risk population. The objective of this review is to report the history of cardiovascular disease and HCM in South Asians, present previously published pathogenic variants, and introduce current efforts to study HCM using induced pluripotent stem cell-derived cardiomyocytes, next-generation sequencing, and gene editing technologies. The authors ultimately hope that this review will stimulate further research, drive novel discoveries, and contribute to the development of personalized medicine with the aim of expanding therapeutic strategies for HCM.
- 1 October 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 572 (2-3) , 189-196
Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation
- 1 October 2007
- Published by Elsevier in European Journal of Pharmacology
- Vol. 572 (2-3) , 189-196
Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation
- 1 May 2007
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 42 (5) , 946-953
Characterization of sinoatrial node in four conduction system marker mice
- 1 May 2007
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 42 (5) , 946-953
Characterization of sinoatrial node in four conduction system marker mice
- 31 May 2006
- Published by Elsevier in Heart Rhythm
- Vol. 3 (5) , S269-269
P5-27: Immunohistochemical characterization of sinoatrial node in three atrioventricular conduction system marker mice
- 31 May 2006
- Published by Elsevier in Heart Rhythm
- Vol. 3 (5) , S269-269
P5-27: Immunohistochemical characterization of sinoatrial node in three atrioventricular conduction system marker mice